Fallopian Tube Endometrioid Adenocarcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Fallopian Tube Endometrioid Adenocarcinoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 10 trials

RecruitingNot Applicable

NCT06466382

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor inform…

Switzerland60 participantsStarted 2025-03-31

Treatment: Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling, Carboplatin / Paclitaxel Chemotherapy

RecruitingPhase 1/2

NCT05920798

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalpha…

United States40 participantsStarted 2023-09-28

Treatment: Biopsy, Biospecimen Collection

RecruitingPhase 3

NCT06580314

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homolo…

United States880 participantsStarted 2025-03-12

Treatment: Bevacizumab, Biospecimen Collection

RecruitingPhase 2

NCT04919629

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr…

This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab a…

United States60 participantsStarted 2023-04-27

Treatment: Bevacizumab, Biopsy

RecruitingPhase 2

NCT05231122

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re…

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ova…

United States80 participantsStarted 2024-03-12

Treatment: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab

RecruitingPhase 3

NCT04575935

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal…

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian t…

United States580 participantsStarted 2020-08-05

Treatment: Chemotherapy, Laparotomy

All recent trials (93 shown)

Active — Not RecruitingPhase 3

NCT02446600

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usu…

This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating…

United States579 participantsStarted 2016-03-28

Treatment: Biospecimen Collection, Carboplatin

Active — Not RecruitingPhase 2/3

NCT02839707

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O…

This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovari…

United States444 participantsStarted 2017-06-23

Treatment: Atezolizumab, Bevacizumab

Fallopian Tube Endometrioid Adenocarcinoma

Trial phase breakdown

Trial status

Actively recruiting — 10 trials

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr…

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re…

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal…

All recent trials (93 shown)

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usu…

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O…

Trial phase breakdown

Trial status

Actively recruiting — 10 trials

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr…

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re…

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal…

All recent trials (93 shown)

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usu…

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O…

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovaria…

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recu…

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Pl…

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansi…

Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Pri…

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Prima…

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovaria…

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Prim…

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and…

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Pe…

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients Wit…

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV…

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer